SKU(재고 관리 코드):LMB539Ra
Magnetic Luminex Assay Kit for Serum Amyloid P Component (SAP) ,etc.
Magnetic Luminex Assay Kit for Serum Amyloid P Component (SAP) ,etc.
Product No.
LMB539Ra
Organism Species
Rattus norvegicus (Rat).
Sample Type
Serum, plasma and other biological fluids.
Test Method
Double-antibody Sandwich
Assay Length
3.5h
Detection Range
0.39-400ng/mL
Sensitivity
The minimum detectable dose of this kit is typically less than 0.13 ng/mL.
UOM
1Plex 2Plex 3Plex 4Plex 5Plex 6Plex 7Plex 8Plex
Specificity
This assay has high sensitivity and excellent specificity for detection of Serum Amyloid P Component (SAP) ,etc..
No significant cross-reactivity or interference between Serum Amyloid P Component (SAP) ,etc. and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Serum Amyloid P Component (SAP) ,etc. and the recovery rates were calculated by comparing the measured value to the expected amount of Serum Amyloid P Component (SAP) ,etc. in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 91-101 | 94 |
EDTA plasma(n=5) | 87-98 | 91 |
heparin plasma(n=5) | 95-105 | 101 |
sodium citrate plasma(n=5) | 90-101 | 95 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Serum Amyloid P Component (SAP) ,etc. were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Serum Amyloid P Component (SAP) ,etc. were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Serum Amyloid P Component (SAP) ,etc. and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 83-91% | 97-105% | 79-96% | 83-92% |
EDTA plasma(n=5) | 81-103% | 89-104% | 94-103% | 97-104% |
heparin plasma(n=5) | 94-103% | 80-101% | 78-104% | 84-96% |
sodium citrate plasma(n=5) | 89-97% | 84-101% | 81-91% | 97-105% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
96-well plate | 1 | Plate sealer for 96 wells | 4 |
Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
Pre-Mixed Magnetic beads (22#:SAP) | 1 | Analysis buffer | 1×20mL |
Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
Magazine | Citations |
Journal of Vascular Surgery | Circulation levels of acute phase proteins in patients with Takayasu arteritis PubMed: 20100644 |
Journal of Proteome Research | Combined Proteomic and Metabolomic Profiling of Serum Reveals Association of the Complement System with Obesity and Identifies Novel Markers of Body Fat Mass Changes ACS: pr2005555 |
Liver International | Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 3-D DIGE Pubmed: 23944848 |
Journal of Proteome Research | Targeted proteomics predict a sustained complete-response after transarterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma: a prospective cohort study pubmed:28112944 |
American Journal of Reproductive Immunology | Amniotic fluid pentraxins: Potential early markers for identifying intra‐amniotic inflammatory complications in preterm pre‐labor rupture of membranes pubmed:29193454 |
Theranostics | Serum amyloid P component therapeutically attenuates atherosclerosis in mice via its effects on macrophages Pubmed:29930724 |
J Med Primatol | Proteopathic lesions in the brain of a super©\aged chimpanzee (Pan troglodytes) 34096618 |
Clinical and Experimental Immunology | Clinical significance of differential serum-signatures for early prediction of severe dengue among Eastern Indian patients Pubmed:35348620 |
Catalog No. | Related products for research use of Rattus norvegicus (Rat) Organism species | Applications (RESEARCH USE ONLY!) |
RPB539Ra01 | Recombinant Serum Amyloid P Component (SAP) | Positive Control; Immunogen; SDS-PAGE; WB. |
PAB539Ra01 | Polyclonal Antibody to Serum Amyloid P Component (SAP) | WB; IHC; ICC; IP. |
MAB539Ra21 | Monoclonal Antibody to Serum Amyloid P Component (SAP) | WB; IHC; ICC; IP. |
SEB539Ra | ELISA Kit for Serum Amyloid P Component (SAP) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMB539Ra | Magnetic Luminex Assay Kit for Serum Amyloid P Component (SAP) ,etc. | Magnetic Luminex Assay for Antigen Detection. |